PRISM MarketView

Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial

NEW YORK, N.Y., June 5, 2024 - PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting Soligenix Inc’s (Nasdaq: SNGX) key achievements and pathway to regulatory success through its lead product candidat...

5 June 2024

PRISM MarketView Highlights Soligenix’s Promising HyBryte™ Replication Trial: Setting the Stage for Success

New York, June 4, 2024 - PRISM MarketView - The late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX), is working to address a critical gap in treatment of rare and chronic cancer, cutaneous T-cell lymphoma (CTCL). CTCL is a cancer of the white blood cells...

4 June 2024

FDA Fast Track for Quince Therapeutics EryDex System for Rare Disease

New York, June 4, 2024 - PRISM MarketView - Shares in biotechnology company, Quince Therapeutics (Nasdaq: QNCX), climbed on Monday morning before settling up +5.66% at the close of trading, and rising an additional 3.80% after the market close. The company announced that...

4 June 2024

Designer Brands (DBI) Provides Q1 Results, Investors “Fashion” A Sell Off on News, Down ~20%

New York, June 4, 2024 - PRISM MarketView - Today the global designer, manufacturer and retailer of footwear and accessories Designer Brands, Inc. (DBI), provided their Q1 financial results that missed on EPS ($0.08 vs StreetAccount $0.13) but beat on revenues ($746.6M v...

4 June 2024

Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study

New York, June 3, 2024 - PRISM MarketView - Oncocyte Corporation’s (Nasdaq: OCX) VitaGraft (TM) diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial eval...

3 June 2024

PRISM MedDevice Mover Microbot (MBOT) Up ~98% on FDA Approval For Human Clinical Trial

New York, June 3, 2024 - PRISM MarketView - The PRISM MedDevice Index company and the developer of the innovative LIBERTY® Endovascular Robotic Surgical System, Microbot Medical (MBOT) has announced that it has received approval from the U.S. Food and Drug Administration...

3 June 2024

Candel Therapeutics Secures FDA Orphan Drug Designation for Glioma Candidate

New York, June 3, 2024 - PRISM MarketView - Candel Therapeutics’ (Nasdaq: CADL) share price rose by nearly 10% in intraday trading on Friday after the company announced it had been granted Orphan Drug Designation by the FDA for CAN-3110, a next generation oncolytic viral...

3 June 2024

Iterum Therapeutics Tops PRISM Emerging Women’s Health Index, Receives PDUFA Date from FDA

New York, May 31, 2024 - PRISM MarketView - Clinical-stage pharmaceutical company, Iterum Therapeutics (Nasdaq: ITRM), is topping the PRISM Emerging Women’s Health Index on Friday after the company announced that the FDA has acknowledged receipt of the company’s resubmit...

31 May 2024

Biomea Fusion Completes Enrollment in Type 2 Diabetes Trial

New York, May 31, 2024 - PRISM MarketView - Shares in Biomea Fusion (Nasdaq: BMEA) climbed this week after the company announced it has completed the enrollment of 260 type 2 diabetes in the first three dose expansion arms of its COVALENT-111 study. Biomea is evaluating ...

31 May 2024

Oncocyte’s VitaGraft KidneyTM Utilized in Study Published in Peer-Reviewed Journal, Makes Use-Case for Potential Global Adoption of Test

New York, May 31, 2024 - PRISM MarketView - Oncocyte Corporation’s (Nasdaq: OCX) VitaGraft (TM) Kidney diagnostic test for transplant monitoring has been successfully utilized in a Phase 2 clinical trial published in the peer-reviewed New England Journal of Medicine. The...

31 May 2024